UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

Petitioner, GE Healthcare Ltd.,

v.

Johns Hopkins University,
Patent Owner.

Case No. IPR2026-00069
U.S. Patent No. 11,938,201

PETITIONER'S UPDATED EXHIBIT LIST

EXHIBIT LIST

No.	Exhibit Description
1001	U.S. Patent No. 11,938,201
1002	File History of U.S. Patent No. 11,938,201
1003	Declaration of Dr. Brian Zeglis
1004	U.S. Patent Publication 2010/0098633
1005	U.S. Patent Publication 2012/0009121
1006	Jansen et al., "Extended Structure−Activity Relationship and Pharmacokinetic Investigation of (4-Quinolinoyl)glycyl-2-cyanopyrrolidine Inhibitors of Fibroblast Activation Protein (FAP)," J. Med. Chem, 57:3053–3074 (2014)
1007	Jansen et al., "Selective Inhibitors of Fibroblast Activation Protein (FAP) with a (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine Scaffold," ACS Med. Chem. Lett., 4:491–496 (2013)
1008	Meletta et al., "Evaluation of the Radiolabeled Boronic Acid-Based FAP Inhibitor MIP-1232 for Atherosclerotic Plaque Imaging," Molecules, 20:2081–2099 (2015)
1009	Jamous et al., "Synthesis of Peptide Radiopharmaceuticals for the Therapy and Diagnosis of Tumor Diseases," Molecules, 18:3379–3409 (2013)
1010	Zeglis et al., "A practical guide to the construction of radiometallated bioconjugates for positron emission tomography," Dalton Trans., 40(23):6168–6195 (2011)
1011	Zeglis et al., "Underscoring the Influence of Inorganic Chemistry on Nuclear Imaging with Radiometals," Inorg. Chem., 53:1880–1889 (2013)
1012	Wadas et al., "Coordinating Radiometals of Copper, Gallium, Indium, Yttrium, and Zirconium for PET and SPECT Imaging of Disease," Chem. Rev., 110(5):2858–2902 (2010)
1013	Price et al., "Matching chelators to radiometals for radiopharmaceuticals," Chem. Soc. Rev., 43:260–290 (2014)
1014	Riondato et al., "Chapter 4: Radiopharmaceuticals," Springer International Publishing, (2016)

No.	Exhibit Description
1015	Ross, "The Click Chemistry Approach Applied to Fluorine-18," Current Radiopharmaceuticals, 3:202–223 (2010)
1016	Brennen et al., "Rationale Behind Targeting Fibroblast Activation Protein–Expressing Carcinoma-Associated Fibroblasts as a Novel Chemotherapeutic Strategy," Mol. Cancer Ther., 11(2):257–266 (2012)
1017	Sarko et al., "Bifunctional Chelators in the Design and Application of Radiopharmaceuticals for Oncological Diseases," Current Medicinal Chem., 19:2667–2688 (2012)
1018	Fichna et al., "Synthesis of Target-Specific Radiolabeled Peptides for Diagnostic Imaging," Bioconjugate Chem., 14:3–17 (2003)
1019	Schirrmacher et al., "Small Prosthetic Groups in ^{18}F-Radiochemistry: Useful Auxiliaries for the Design of ^{18}F-PET Tracers," Semin. Nucl. Med., 47(5):474–492 (August 2017)
1020	Saha et al., "Chapter 8: Synthesis of PET Radiopharmaceuticals," Springer International Publishing, (2016)
1021	Kettenbach et al., "^{18}F-Labeling Using Click Cycloadditions," BioMed Research International, 2014:1–16 (2014)
1022	Liu et al., "Fibroblast activation protein, A potential therapeutic target in cancer," Cancer Biology & Ther., 13(3):123–129 (2012)
1023	DiMagno et al., "Advanced Fibroblast Activation Protein-Ligand Developments, FAP Imaging Agents: A Review of the Structural Requirements," PET Clin., 18:287–294 (2023)
1024	Hamson et al., "Understanding fibroblast activation protein (FAP): Substrates, activities, expression and targeting for cancer therapy," Proteomics Clin. Appl., 8:454–463 (2014)
1025	O'Brien et al., "Seprase: An overview of an important matrix serine protease," Biochimica et Biophysica Acta, 1784:1130–1145 (2008)
1026	Jia et al., "FAP-α (Fibroblast activation protein-α) is involved in the control of human breast cancer cell line growth and motility via the FAK pathway," BMC Cell Biology, 15(16): 1–14 (2014)

No.	Exhibit Description
1027	Agdeppa et al., "A Review of Imaging Agent Development," The American Association of Pharmaceutical Scientists (AAPS) J., 11(2):286– 299 (2009)
1028	Mankoff et al., "Tumor Receptor Imaging," J. Nucl. Med., 49:149S–163S (2008)
1029	Ryabtsova et al., "Acylated Gly-(2-cyano)pyrrolidines as inhibitors of fibroblast activation protein (FAP) and the issue of FAP/prolyl oligopeptidase (PREP)-selectivity," Bioorganic & Medicinal Chemistry Letters, 22(10):3412–3417 (2012)
1030	Eder et al., "^{68}Ga-Complex Lipophilicity and the Targeting Property of a Urea-Based PSMA Inhibitor for PET Imaging," Bioconjugate Chem., 23:688–697 (2012)
1032	Fani et al., "Radiolabeled Peptides: Valuable Tools for the Detection and Treatment of Cancer," Theranostics, 2(5):481–501 (2012)
1033	Mach et al., "Challenges for Developing PET Tracers: Isotopes, Chemistry, and Regulatory Aspects," 5(2): 131–153 (2010)
1034	Meyer et al., "Click Chemistry and Radiochemistry: The First 10 Years," Bioconjugate Chem., 27:2791–2807 (2016)
1035	Marquis et al., "Abstract #4467: Targeting tumor microenvironment with radiolabeled inhibitors of seprase (FAP\#945;)," Cancer Chem., 69:4467 (2009)
1036	Maurer et al., "Current use of PSMA-PET in prostate cancer management," Nature Reviews: Urology, 13:226–235 (2016)
1037	Karakatsanis et al., "Dosage optimization in positron emission tomography: state-of-the-art methods and future prospects," Am. J. Nucl. Med. Mol. Imaging, 5(5):527–547 (2015)
1038	LeBeau et al., "Targeting the cancer stroma with a fibroblast activation protein-activated promelittin protoxin," Mol. Cancer Ther. 8(5):1378–1386 (2009)
1039	Nelson et al., "Good practices for ^{68}Ga radiopharmaceutical production," EJNMMI Radiopharmacy and Chem., 7(1):1–26 (2022)
1040	Meyer et al., "Exploring Structural Parameters for Pretargeting Radioligand Optimization," J. Med. Chem., 60:8201–8217 (2017)

No.	Exhibit Description
1041	Gorrell, "Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders," Clinical Science, 108:1–16 (2005)
1042	Kiesewetter et al., "Automated radiochemical synthesis of [^{18}F]FBEM: A thiol reactive synthon for radiofluorination of peptides and proteins," Appl. Radiation and Isotopes, 69(2): 410–414 (2011)
1043	Chansaenpak et al., "[^{18}F]-NHC-BF_3 adducts as water stable radio-prosthetic groups for PET imaging," Chem. Commun., 51(62):12439–12442 (2015)
1044	U.S. Patent Publication 2014/0357650
1045	Ji et al., "Tumor fibroblast specific activation of a hybrid ferritin nanocage-based optical probe for tumor microenvironment imaging," Small J., 9(14):2427–2431 (2013)
1046	Wilson et al., "Chapter 1, Dipeptidyl Peptidases: Substrates and Therapeutic Targeting in Human Health and Disease," Royal Society of Chemistry, (2012)
1047	Tsai et al., "Substituted 4-carboxymethylpyroglutamic Acid Diamides as Potent and Selective Inhibitors of Fibroblast Activation Protein," J. Med. Chem. 53(18):6572–6583 (2010)
1048	International Publication 2010/108125
1051	Harris et al., "Impact of 2-Deoxy-2[F-18]Fluoro-D-Glucose Positron Emission Tomography on the Management of Patients with Advanced Melanoma," Mol. Imaging Biol., 7(4):304–308 (2005)
1052	Zhou et al., "Radiolabeled Cyclic RGD Peptides as Radiotracers for Imaging Tumors and Thrombosis by SPECT," Theranostics, 1:58-82 (2011)
1053-1061	*Reserved*
1062 [NEW]	Declaration of Amit Bhatla

Dated: June 9, 2026

Respectfully submitted,

/Jeffrey P. Kushan/

Jeffrey P. Kushan
Reg. No. 43,401
Sidley Austin LLP
1501 K Street, N.W.
Washington, D.C. 20005
jkushan@sidley.com
(202) 736-8914
Attorney for Petitioner

CERTIFICATE OF SERVICE

Pursuant to 37 C.F.R. § 42.6(e), I hereby certify that on this this 9th day of June, 2026, I caused to be served a true and correct copy of the foregoing and any accompanying exhibits by electronic mail on the following counsel:

Eldora L. Ellison, eellison-PTAB@sternekessler.com
Olga A. Partington, opartington-PTAB@sternekessler.com
Christopher M. Gallo, cgallo-PTAB@sternekessler.com
Christina E. Dashe, cdashe-PTAB@sternekessler.com
PTAB@sternekessler.com

Dated: June 9, 2026

Respectfully submitted,

/Jeffrey P. Kushan/

Jeffrey P. Kushan
Reg. No. 43,401
Sidley Austin LLP
1501 K Street, N.W.
Washington, D.C. 20005
jkushan@sidley.com
(202) 736-8914
Attorney for Petitioner